adenine has been researched along with Bone Diseases in 15 studies
Bone Diseases: Diseases of BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 6.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| " Here, we established a rat model with secondary hyperparathyroidism (SHPT) and bone disease induced by adenine and a high phosphorous diet and analyzed the skeletal characteristics." | 3.88 | A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet. ( Chen, Q; Liu, BC; Lv, LL; Ni, HF; Ni, LH; Song, KY; Tang, RN; Wang, B; Wang, FM; Wang, LT; Wu, M, 2018) |
| "Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 2.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
| " The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste." | 1.40 | Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. ( , 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, H | 3 |
| Goto, M | 3 |
| Nishimura, G | 3 |
| Morimoto, N | 3 |
| Tokushima, H | 3 |
| Horii, Y | 3 |
| Takahashi, N | 3 |
| Diwan, V | 1 |
| Brown, L | 1 |
| Gobe, GC | 1 |
| Ni, LH | 1 |
| Tang, RN | 1 |
| Lv, LL | 1 |
| Wu, M | 1 |
| Wang, B | 1 |
| Wang, FM | 1 |
| Ni, HF | 1 |
| Song, KY | 1 |
| Wang, LT | 1 |
| Chen, Q | 1 |
| Liu, BC | 1 |
| Ichchou, L | 1 |
| Rist, S | 1 |
| Lespessailles, E | 1 |
| Prié, D | 1 |
| Benhamou, CL | 1 |
| Puthanakit, T | 1 |
| Siberry, GK | 1 |
| Mangioni, D | 1 |
| Bandera, A | 1 |
| Muscatello, A | 1 |
| Squillace, N | 1 |
| Crivellaro, C | 1 |
| Guerra, L | 1 |
| Messa, C | 1 |
| Gori, A | 1 |
| Lockhart, SM | 1 |
| Drevets, DA | 1 |
| Maggi, P | 1 |
| Montinaro, V | 1 |
| Leone, A | 1 |
| Fasano, M | 1 |
| Volpe, A | 1 |
| Bellacosa, C | 1 |
| Grattagliano, V | 1 |
| Coladonato, L | 1 |
| Lapadula, G | 1 |
| Santantonio, T | 1 |
| Angarano, G | 1 |
| Gervasoni, C | 1 |
| Minisci, D | 1 |
| Meraviglia, P | 1 |
| Baldelli, S | 1 |
| Clementi, E | 1 |
| Rizzardini, G | 1 |
| Cattaneo, D | 1 |
| Foster, C | 1 |
| Lyall, H | 1 |
| Olmscheid, B | 1 |
| Pearce, G | 1 |
| Zhang, S | 1 |
| Gibb, DM | 1 |
| Carr, A | 1 |
| Hoy, J | 1 |
| Cotter, AG | 1 |
| Powderly, WG | 1 |
| Brim, NM | 1 |
| Cu-Uvin, S | 1 |
| Hu, SL | 1 |
| O'Bell, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for adenine and Bone Diseases
| Article | Year |
|---|---|
Adenine-induced chronic kidney disease in rats.
Topics: Adenine; Animals; Bone Diseases; Cardiovascular Diseases; Disease Models, Animal; Disease Progressio | 2018 |
Bone health in children and adolescents with perinatal HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Bone Density; Bone Diseases; Child; HIV Infections; Humans; Or | 2013 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Dis | 2011 |
11 other studies available for adenine and Bone Diseases
| Article | Year |
|---|---|
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
A rat model of SHPT with bone abnormalities in CKD induced by adenine and a high phosphorus diet.
Topics: Adenine; Animals; Bone and Bones; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Diet; Disea | 2018 |
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow | 2013 |
Focal bone lesions in HIV-positive patient treated with tenofovir.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonat | 2014 |
Reversible bone lesions induced by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Bone Diseases; Female; Humans; Organophosphonates; Radionuclide Imaging; Tenofovir | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Hu | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio | 2015 |
Determinants of bone diseases in tenofovir-treated HIV patients.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Tenofovir | 2016 |
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe | 2009 |
Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Female; Fractures, Bone; HIV Infection | 2010 |
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Fanconi Syndrome; Fe | 2007 |